Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
A combination of low-dose anlotinib and immune checkpoint inhibitors as second-line or later treatment for ES-SCLC may achieve longer PFS and OS and have manageable AEs.
Authors
- Tiepeng Li
- Lu Han (ORCID: https://orcid.org/0000-0003-4688-0907)
- Xiaomin Fu
- Shumin Yuan
- Qin Peng (ORCID: https://orcid.org/0000-0002-7710-4639)
- Lingdi Zhao (ORCID: https://orcid.org/0000-0003-0158-3781)
- Hongqin You
- Zibing Wang
- Han Wu
- Benling Xu
- Xiance Tang
- Han Li (ORCID: https://orcid.org/0009-0003-6884-2714)
- Yichen Ma
- Yajie Wang
Institutions
- Nanchang University (CN)
- Xinjiang Medical University (CN)
- Zhengzhou University (CN)
- Henan Cancer Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Cancer Innovation
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1002/cai2.155
- Citations
- 3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China